Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pediatric Blood & Cancer

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.25426PMID 25649118
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical application of asparaginase activity levels following treatment with pegaspargase

  2015cited by this paper
• Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.

  2014cited by this paper
• How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.

  2014cited by this paper
• Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

  2013cited by this paper
• Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.

  2007cited by this paper
• Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.

  2005cited by this paper
• Preparing for the cancer revolution.

  2005cited by this paper
• Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children's Cancer Group Study CCG-1961

  2004cited by this paper
• A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.

  2002cited by this paper
• L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.

  1981cited by this paper

• Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring

  2023cites this paper
• Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia

  2020cites this paper
• A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage

  2019cites this paper
• Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma

  2018cites this paper
• Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia

  2018cites this paper
• Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU

  2017cites this paper
• Catalyzing improvements in ALL therapy with asparaginase.

  2017cites this paper
• Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia

  2017cites this paper
• Reply to: Colon LB, Perissinotti A, Santarosa M, Marini BL. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy

  2015cites this paper